Sung-Youn Chun1,2, Dong Wook Kim3, Sang Ah Lee1,2, Su Jung Lee2,4, Jung Hyun Chang2,5, Yoon Jung Choi2,6, Seong Woo Kim2,7, Sun Ok Song2,8. 1. Research and Analysis Team, National Health Insurance Service Ilsan Hospital, Goyang, Korea. 2. Research Institute of National Health Insurance Service Ilsan Hospital, Goyang, Korea. 3. Department of Big Data, National Health Insurance Service, Wonju, Korea. 4. Medical Library, National Health Insurance Service Ilsan Hospital, Goyang, Korea. 5. Department of Otolaryngology-Head and Neck Surgery, National Health Insurance Service Ilsan Hospital, Goyang, Korea. 6. Department of Pathology, National Health Insurance Service Ilsan Hospital, Goyang, Korea. 7. Department of Physical Medicine and Rehabilitation, National Health Insurance Service Ilsan Hospital, Goyang, Korea. 8. Division of Endocrinology and Metabolism, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Korea.
Abstract
BACKGROUND: This study aimed to determine the infection risk of coronavirus disease 2019 (COVID-19) in patients with diabetes (according to treatment method). METHODS: Claimed subjects to the Korean National Health Insurance claims database diagnosed with COVID-19 were included. Ten thousand sixty-nine patients with COVID-19 between January 28 and April 5, 2020, were included. Stratified random sampling of 1:5 was used to select the control group of COVID-19 patients. In total 50,587 subjects were selected as the control group. After deleting the missing values, 60,656 subjects were included. RESULTS: Adjusted odds ratio (OR) indicated that diabetic insulin users had a higher risk of COVID-19 than subjects without diabetes (OR, 1.25; 95% confidence interval [CI], 1.03 to 1.53; P=0.0278). In the subgroup analysis, infection risk was higher among diabetes male insulin users (OR, 1.42; 95% CI, 1.07 to 1.89), those between 40 and 59 years (OR, 1.66; 95% CI, 1.13 to 2.44). The infection risk was higher in diabetic insulin users with 2 to 4 years of morbidity (OR, 1.744; 95% CI, 1.003 to 3.044). CONCLUSION: Some diabetic patients with certain conditions would be associated with a higher risk of acquiring COVID-19, highlighting their need for special attention. Efforts are warranted to ensure that diabetic patients have minimal exposure to the virus. It is important to establish proactive care and screening tests for diabetic patients suspected with COVID-19 for timely disease diagnosis and management.
BACKGROUND: This study aimed to determine the infection risk of coronavirus disease 2019 (COVID-19) in patients with diabetes (according to treatment method). METHODS: Claimed subjects to the Korean National Health Insurance claims database diagnosed with COVID-19 were included. Ten thousand sixty-nine patients with COVID-19 between January 28 and April 5, 2020, were included. Stratified random sampling of 1:5 was used to select the control group of COVID-19patients. In total 50,587 subjects were selected as the control group. After deleting the missing values, 60,656 subjects were included. RESULTS: Adjusted odds ratio (OR) indicated that diabetic insulin users had a higher risk of COVID-19 than subjects without diabetes (OR, 1.25; 95% confidence interval [CI], 1.03 to 1.53; P=0.0278). In the subgroup analysis, infection risk was higher among diabetes male insulin users (OR, 1.42; 95% CI, 1.07 to 1.89), those between 40 and 59 years (OR, 1.66; 95% CI, 1.13 to 2.44). The infection risk was higher in diabetic insulin users with 2 to 4 years of morbidity (OR, 1.744; 95% CI, 1.003 to 3.044). CONCLUSION: Some diabeticpatients with certain conditions would be associated with a higher risk of acquiring COVID-19, highlighting their need for special attention. Efforts are warranted to ensure that diabeticpatients have minimal exposure to the virus. It is important to establish proactive care and screening tests for diabeticpatients suspected with COVID-19 for timely disease diagnosis and management.
Authors: Brenda Eskenazi; Stephen Rauch; Enrico Iurlaro; Robert B Gunier; Albertina Rego; Michael G Gravett; Paolo Ivo Cavoretto; Philippe Deruelle; Perla K García-May; Mohak Mhatre; Mustapha Ado Usman; Mohamed Elbahnasawy; Saturday Etuk; Raffaele Napolitano; Sonia Deantoni; Becky Liu; Federico Prefumo; Valeria Savasi; Patrícia F Marques; Eric Baafi; Ghulam Zainab; Ricardo Nieto; Berta Serrano; Muhammad Baffah Aminu; Jorge Arturo Cardona-Perez; Rachel Craik; Adele Winsey; Gabriela Tavchioska; Babagana Bako; Daniel Oros; Caroline Benski; Hadiza Galadanci; Mónica Savorani; Manuela Oberto; Loïc Sentilhes; Milagros Risso; Ken Takahashi; Carmen Vecciarelli; Satoru Ikenoue; Anil K Pandey; Constanza P Soto Conti; Irene Cetin; Vincent Bizor Nachinab; Ernawati Ernawati; Eduardo A Duro; Alexey Kholin; Michelle L Firlit; Sarah Rae Easter; Joanna Sichitiu; Yetunde John-Akinola; Roberto Casale; Hellas Cena; Josephine Agyeman-Duah; Paola Roggero; Ana Langer; Zulfiqar A Bhutta; Stephen H Kennedy; Jose Villar; Aris T Papageorghiou Journal: Am J Obstet Gynecol Date: 2021-12-20 Impact factor: 10.693